Protein Kinase Inhibitors: all 15,278 studies that test it

Page 75 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic DermatitisWithdrawnNCT06390722Phase 3
• Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654CompletedNCT06389955Phase 1
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabActive, not recruitingNCT06389136Phase 3
• TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant PatientsTerminatedNCT06388759Phase 1
• A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT06388564Phase 2
• A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy SubjectsCompletedNCT06387966Phase 1
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingNCT06385496Phase 2
• A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult FemalesCompletedNCT06380205Phase 1
• A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy ParticipantsCompletedNCT06378658Phase 1
• Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells CancerTerminatedNCT06377722Phase 2
• First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerCompletedNCT06375707Phase 2
• A Food Effect Study of SPH5030 Tablets.CompletedNCT06372223Phase 1
• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.Active, not recruitingNCT06372145Phase 3
• A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without FoodCompletedNCT06369454Phase 1
• Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Phase 2
• A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy ParticipantsCompletedNCT06360211Phase 1
• Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical TrialActive, not recruitingNCT06356597Phase 2
• Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1CompletedNCT06354387Phase 1
• A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentCompletedNCT06352528Phase 1
• ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT06351644Phase 1/2
• ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCTerminatedNCT06351332Phase 1
• A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy VolunteersCompletedNCT06348355Phase 1
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Active, not recruitingNCT06346067Phase 3
• Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe ADCompletedNCT06345404Phase 1
• A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy ParticipantsCompletedNCT06342700Phase 1
• Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With OsteosarcomaTerminatedNCT06341712Phase 2
• A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid TumorsTerminatedNCT06337630Phase 1
• A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)CompletedNCT06333860Phase 4
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT06332534Phase 3
• Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mgCompletedNCT06331715Phase 4
• A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy ParticipantsCompletedNCT06329895Phase 1
• Combination of Sotyktu and Enstilar for Plaque PsoriasisCompletedNCT06329258Phase 4
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerActive, not recruitingNCT06328738Phase 1
• Erdafitinib in Metastatic Steroid-cell Ovarian CancerCompletedNCT06328491Not applicable
• A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT06328439Phase 1
• Vitiligo Treatment by Targeting TYK2 Mediated ResponsesActive, not recruitingNCT06327321Phase 2
• A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT06323356Phase 3
• A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021CompletedNCT06322706Phase 1
• Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic KeratosisCompletedNCT06319794Phase 2
• Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaActive, not recruitingNCT06318286Phase 2
• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT06313593Phase 1
• A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.CompletedNCT06310304Phase 1
• Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation StudyCompletedNCT06310057Phase 4
• Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06308913Early Phase 1
• A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory NeuroblastomaWithdrawnNCT06308575Phase 2
• A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsActive, not recruitingNCT06308419Phase 1
• Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)CompletedNCT06308263Phase 1
• A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursActive, not recruitingNCT06305247Phase 1/2
• Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasActive, not recruitingNCT06300528Phase 2
• Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLCActive, not recruitingNCT06300424Phase 2
• A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid TumorsActive, not recruitingNCT06299124Phase 1
• A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)CompletedNCT06295432Phase 2
• TGRX-326 Pharmacokinetic Drug InteractionCompletedNCT06294561Phase 1
• The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnNCT06291415Phase 1
• A Study of the Interaction of Other Drugs With TAK-279 in Healthy AdultsCompletedNCT06290050Phase 1
• Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayTerminatedNCT06287463Phase 1
• Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative NeoplasmsWithdrawnNCT06284460Phase 1/2
• Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid TherapyCompletedNCT06283550Phase 2
• Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesActive, not recruitingNCT06282874Phase 4
• Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT06281886Phase 2
• TYK2 Inhibition in Paradoxical PsoriasisTerminatedNCT06281106Phase 2/3
• Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaActive, not recruitingNCT06279403Phase 2
• A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic CancerCompletedNCT06278493Phase 1/2
• Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.CompletedNCT06278402Phase 3
• A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.CompletedNCT06277245Phase 3
• A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)Active, not recruitingNCT06276998Phase 3
• Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT06271616Phase 2
• Study of IK-595 in RAS- or RAF-altered Advanced TumorsTerminatedNCT06270082Phase 1
• Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AMLTerminatedNCT06268574Phase 2
• Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerActive, not recruitingNCT06268210Phase 2
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsTerminatedNCT06264921Phase 1
• A Study of TAK-279 in Healthy Adults on the Effect on ECG MeasurementsCompletedNCT06258265Phase 1
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Phase 1
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06254950Phase 2
• BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsCompletedNCT06253195Phase 1
• Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06251180Phase 1
• A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer StudiesActive, not recruitingNCT06246643Phase 2
• RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic NeoplasmsActive, not recruitingNCT06243458Phase 2
• Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar ExtractionCompletedNCT06241742Phase 2
• A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)Active, not recruitingNCT06240351Phase 4
• HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic CholangiocarcinomaActive, not recruitingNCT06239532Phase 2
• First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingNCT06239467Phase 1
• A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid TumorStatus unknownNCT06239298Phase 1/2
• A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid TumorsCompletedNCT06231550Phase 1
• Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).WithdrawnNCT06227897Phase 2
• Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)TerminatedNCT06222034Phase 1
• A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male ParticipantsCompletedNCT06221475Phase 1
• Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid TumorsActive, not recruitingNCT06220318Phase 1/2
• Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)WithdrawnNCT06219733Phase 2
• A Study of Copanlisib in Combination with Degarelix in People with Prostate CancerWithdrawnNCT06218667Phase 1/2
• Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)SuspendedNCT06214793Phase 2
• A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamCompletedNCT06213831Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult ParticipantCompletedNCT06213818Phase 1
• A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06212999Phase 3
• A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsCompletedNCT06208124Phase 1/2
• Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Phase 2
• A SHR0302 BA Study on Healthy SubjectsCompletedNCT06202612Phase 1
• Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and IrinotecanActive, not recruitingNCT06199973Phase 3
• A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic CancerTerminatedNCT06199466Phase 1
• A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal CancersTerminatedNCT06194877Phase 1

← Protein Kinase Inhibitors overview